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A substantial minority of patients surviving acquired brain injury develop a state of sympathetic 
hyperactivity that may persist for weeks or months, consisting of periodic episodes of increased heart rate 
and blood pressure, sweating, hyperthermia, and motor posturing, often in response to external stimuli. 
The unifying term for the syndrome, Paroxysmal Sympathetic Hyperactivity (PSH), and clear diagnostic 
criteria defined by expert consensus, were only recently established. PSH has predominantly been 
described after traumatic brain injury, where it is associated with worse outcome. The pathophysiology is 
incompletely understood, although most researchers consider it a disconnection phenomenon with 
paroxysms driven by a loss of inhibitory control over excitatory autonomic centers. While therapeutic 
strategies to mitigate the sympathetic outbursts have been proposed, their effects on PSH are incomplete, 
inconsistent, and unpredictable; and influence on outcome unknown. Drug combinations are frequently 
used, and chosen based on local custom, rather than objective evidence.  New rigorous tools may allow a 
better characterization of patients with PSH for future trials of therapy.   
  
 3 
Introduction 
Excessive sympathetic nervous system activity can develop after severe acquired brain injury, with about 
80% of cases occurring after traumatic brain injury (TBI). This condition can present dramatically,1 with 
paroxysmal tachycardia, arterial hypertension, tachypnea, hyperthermia, and decerebrate posturing, 
precipitated by afferent stimulation. It was first described in TBI by Wilder Penfield 2, and the assumption 
of an epileptic etiology gave the syndrome its first name, ‘mesencephalic seizures’. In over 350 
subsequently published cases up to 20103 in the critical care and rehabilitation literature, the same 
syndrome had over 31 different labels, some more descriptive (e.g. ‘dysautonomia’, ‘autonomic storms’, 
or ‘sympathetic storms’), some referring to an assumed (epileptic) mechanism (e.g. ‘autonomic seizures’), 
or to the site of damage (e.g. ‘hypothalamic storms’). 3–6  This lack of a clear terminology and definition 
were probably both cause and consequence of the under-recognition of this syndrome, despite its 
relatively high incidence after severe brain damage 7,8, the significant association with morbidity 9–12, and 
its high health care and societal costs 7.  It might also explain the slow progress in understanding its 
pathophysiology, further compounded by a failure to distinguish between mixed 
parasympathetic/sympathetic,13 and pure sympathetic hyperactivity, with conflation of both in a single 
diagnosis for many decades.3 Although conclusive evidence of the absence of parasympathetic 
involvement is unavailable, the current consensus is that autonomic hyperactivity in this syndrome only 
concerns the sympathetic division.3,12,14  
In 2010 the term ‘paroxysmal sympathetic hyperactivity’ (PSH), introduced in 2007 by Alejandro Rabinstein 
12, was adopted as the single unifying term for this condition 3. Four years later, in 2014, 60 years after the 
first published case, an expert group 15 established a rigorous conceptual definition and diagnostic criteria. 
These criteria should provide a foundation for more systematic research on this clinical syndrome and its 
management.  
 
Several different classes of agents, acting at a range of molecular targets have been used in PSH, with 
varying success in each case.  The syndrome of PSH is likely to be mechanistically heterogeneous, and 
identifying the dominant pathophysiology that is responsible for the clinical picture in any given patient 
could allow more rational matching of patients to therapies, and move towards precision medicine in PSH. 
The recent development of clear diagnostic criteria for the condition has provided the essential first step 
in such an exercise, since it clearly defines the initial population of patients who might be the subject of 
such therapeutic stratification.   
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The purpose of this Series paper is to provide an overview of the existing literature on PSH, its causes, 
consequences, pathophysiology, and diagnosis; and to discuss the current evidence on therapeutic 
options. Although the dominant underlying aetiology in PSH is TBI, insights obtained from patients with 
other aetiologies of disease who satisfy the criteria for PSH show substantial commonalities in 
pathophysiology and therapy response, and therefore PSH of all causes is covered here.  
 
Definition and diagnostic criteria  
Between 1993 and 2008, 9 sets of diagnostic criteria for this syndrome were published,9,10,12,16–21 which 
differed with regards to timing of occurrence or assessments relative to the injury, the number of clinical 
features required, and the degree of deviation from normal of clinical parameters (heart rate, blood 
pressure, temperature, etc.).22  An international consensus process in 201415 addressed confusion 
regarding nomenclature, produced diagnostic criteria, developed a diagnostic tool, and reached 
agreement on the adoption of the term ‘Paroxysmal Sympathetic Hyperactivity (PSH)’ as a label for this 
condition, which was further defined as:  
 
“A syndrome, recognized in a subgroup of survivors of severe acquired brain injury, of 
simultaneous, paroxysmal transient increases in sympathetic (elevated heart rate, blood pressure, 
respiratory rate, temperature, sweating) and motor (posturing) activity.”  
 
The Expert Group selected 11 of 16 previously reviewed features22 as pathognomonic of PSH 
(Supplementary Table 1), and proposed a clinical scoring system - the PSH assessment measure (PSH-AM) 
(Table 1) - as an aid to diagnostic consistency. The PSH-AM consisted of two separate constructs: first, the 
clinical feature scale (CFS), to score the presence and severity of excess adrenergic and motor activity; and 
second, the diagnosis likelihood tool (DLT), to score the likelihood of the presence of PSH. A paediatric 
adaptation of the CFS has also been proposed (Supplementary Table 2).23  While useful, a definition by 
consensus still has limitations, and a clear link with pathophysiology, the independent contribution of PSH 
to clinical outcomes, and a more precise definition of the duration of a paroxysm, are currently lacking.  
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A. 
Clinical Feature Scale score:    0       1      2    3 
Heart rate (per min) <100 100–119 120–139 >140 
Respiratory rate (per min) <18 18–23 24–29 >30 
Systolic blood pressure (mmHg) <140 140–159 160–179 >180 
Temperature (0C) <37·0 37·0–37·9 38·0–38·9 >39·0 
Sweating Absent Mild Moderate Severe 
Posturing during episodes Absent Mild Moderate Severe 
 
B. 
Diagnosis Likelihood Tool: one point per feature present 
Antecedent acquired brain injury 
Clinical features occur simultaneously 
Episodes are paroxysmal in nature 
Sympathetic over-reactivity to normally non-painful stimuli 
Absence of parasympathetic features during episodes 
Features persist >3 consecutive days 
Features persist >2 weeks post-brain injury 
>2 episodes daily 
Absence of other presumed causes of features 
Features persist despite treatment of alternative differential diagnoses 
Medication administered to decrease sympathetic features 
 
C. 
Interpretation of scores  
 CSF subtotal=sum of CSF scores for each of the six features (0–3 points for individual features; 
maximum subtotal=18); CSF subtotal severity scores: 0=nil; 1–6=mild; 7–12=moderate; >13=severe    
 DLT subtotal=sum of points for each feature present (one point per feature; maximum subtotal=11) 
 PSH–AM=CFS subtotal + DLT subtotal; PSH–AM <8=PSH unlikely; 8–16=PSH possible; >17=PSH 
probable 
Figure 2. The Paroxysmal Sympathetic Hyperactivity–Assessment Measure  
The Paroxysmal Sympathetic Hyperactivity–Assessment Measure (PSH–AM) is calculated using two 
constructs—the Clinical Feature Scale (CFS), which measures the intensity of the cardinal features 
identified as crucial to PSH, and the Diagnosis Likelihood Tool (DLT), based on the presence of contextual 
attributes (identified by expert consensus), which indicates the likelihood that the observed features are 
due to PSH. The combined CFS and DLT scores provide the PSH–AM score, which is an estimate of the 
probability of a diagnosis of PSH. Adapted from Baguley et al,15 by permission of Mary Ann Liebert, Inc. 
 
 
PSH has been described at all stages following brain injury - from early critical care through to the 
rehabilitation phase. Patients are often sedated acutely to minimize secondary brain injury, and classical 
features of PSH may not be manifest until sedation has been weaned. Despite this, the diagnosis may  be 
made as early as within the first week post-TBI, even while patients remain sedated.24 While patients may 
exhibit features of PSH in the absence of provocation, it is far more common for these to be provoked by 
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non-noxious stimuli, or present as a pathologically prolonged physiological responses to noxious stimuli, 
which in the absence of PSH might only result in short lived responses in heart rate and blood pressure.   
The duration of the paroxysmal phase is variable, ranging from less than 2 weeks to many months, after 
which the syndrome may “burn out”, leaving, in many cases, residual dystonia and spasticity.18 It remains 
unclear whether the residual spasticity is truly part of the sequelae of PSH, or simply the consequence of 
injury to supraspinal motor tracts, which happens to coincide with PSH as both are seen more commonly 
in more severe injury.  It is certainly possible for PSH to resolve without residual spasticity. 
Epidemiology  
A review of all 349 published PSH cases prior to 20103 found that about 80 % followed TBI, 10% postanoxic 
brain injury, 5% stroke, and the remaining 5% occurred in association with hydrocephalus, tumor, 
hypoglycemia, infections or unspecified causes. This high prevalence of TBI-related cases is not completely 
explained by the high absolute incidence of TBI, and may be intrinsically higher when compared to other 
causes of brain injury. One series of consecutive febrile neurocritical care patients reported an incidence 
of 33% post-TBI, compared to 6% after other causes of brain injury.12 Regardless of underlying diagnosis, 
reported incidence rates in other studies, from several countries, range from 8% to 33%.7,9,12,16,25,26 The 
rates of PSH may be changing over time.  A recent Italian survey of 333 patients in a vegetative state after 
massive brain injury21,27 described a decreasing incidence of PSH over time, falling from 32% (for TBI) and 
16% (for other aetiologies) between 1998-2005, to 18% and 7% between 2006-2010. Further studies are 
needed to confirm this trend, and to determine its causes. The literature on PSH in paediatrics is limited, 
but broadly similar.  In a large paediatric case series4,  (n=249), the incidence after TBI was 10%, and  31% 
after cardiac arrest. More recently, Pozzi28 performed a retrospective analysis of all 407 children, admitted 
to their neurorehabilitation unit after discharge from an ICU following acute brain injury, between 2001 
and 2011, and was able to identify 26 cases of PSH, of which 12 after TBI, 9 post-anoxic, and 5  due to other 
causes. One smaller study suggests that PSH is twice as frequent in severe hypoxic injury compared to TBI 
in children17. An even higher incidence of 41% was found in series of 72 children with encephalitis and 
meningo-encephalitis 29.  
 
This wide range in reported incidence underlines the difficulties in estimating the true incidence of PSH. 
Factors that explain large between-study differences include: study design (a subset of severe brain injury 
versus consecutive cases), unit admission criteria, type and severity of brain injury, the choice of diagnostic 
criteria, competing events such as non-survival, and publication bias. The difference in incidence is 
influenced by the timing of assessment,7 with 24% of subjects meeting criteria at day 7 post injury, 
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decreasing to 8% at two weeks, in one study. Furthermore, the perceived incidence in subacute units is 
often higher than in ICU, possibly due to ‘clustering’ effects of patients with more severe injuries being 
preferentially admitted for rehabilitation. In addition, stopping powerful analgesics, mainly opioids, upon 
transfer from the ICU to the rehabilitation center, might unmask PSH symptoms.   
Impact on outcome 
The higher likelihood of PSH after more severe and more diffuse brain injuries with an inherent association 
with worse hospital or long-term clinical outcomes makes the assessment of the independent contribution 
of PSH to this outcome a challenge. Before 1999, reports on the outcome of PSH patients were scarce. In 
a large multicenter study of TBI patients in 1993, autonomic hyperactivity was not an independent risk 
factor for mortality or poor clinical outcome,16 but a subsequent study reported longer hospital stay and 
worse clinical outcome in PSH patients compared to matched controls,18 corroborated in a subsequent 
case series from the same centre.7 In a dedicated institute for patients in a vegetative state, a diagnosis of 
‘dysautonomia’ was associated with a worse Glasgow Outcome Scale (GOS) in both TBI and non-TBI 
patients in two studies separated by 5 years.21,27 A similar association with prolonged hospitalization and 
worse clinical outcome was described in a Chinese study,26 but other studies reported less consistent 
impact on hospitalization outcomes, such as duration of mechanical ventilation, or ICU, hospital, or 
rehabilitation length of stay (LoS); and no  effect on long-term neurological outcome 8,9,30,31. The results of 
these studies are summarized in Table 2.  
Between-study discrepancies may reflect the methodological issues mentioned above, inherent to case 
series. In addition, common outcome measures (such as GOS or Functional Independence Measure (FIM)) 
may be too insensitive to assess subtle differences in neurological status at the worse end of the outcome 
scale. Further, the impact of PSH may reflect a spectrum, with a shorter duration syndrome (which may 
be driven by sedative and opioid withdrawal) not affecting outcome, while longer persistence of the 
syndrome being associated with significant negative consequences for recovery. 24   Available data do not 
allow us to address this hypothesis, or determine whether differences in patient management modulate 
the relationship between PSH and outcome.  Notwithstanding these uncertainties, the overall clinical 
impression is that PSH is an independent risk for poorer neurological outcome. 
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Table 1: Outcomes of patients with and without PSH 
Study details 
(1) 
Duration of 
mechanical 
ventilation 
(2) 
ICU/Hospital 
Length of Stay 
(2) 
Rehabilitation 
Length of Stay 
(2) 
Proportion of 
patients with 
tracheostomy 
(3) 
Incidence 
of 
infections 
(3) 
GOS (4) FIM (4) 
Baguley, TBI 
(35/70)18 NA Longer/Longer Longer NA = Worse Worse 
Fernandez-
Ortega, TBI 
(11/37)9 
Longer Longer / NA NA Higher Higher = NA 
Dolce, 
Vegetative, 
mixed (333)21 
NA Longer/Longer NA NA NA Worse NA 
Hendricks, 
TBI30 Longer NA NA NA Higher = NA 
Lv, TBI 
(16/87)26 = Longer/Longer NA Higher Higher Worse NA 
Fernandez-
Ortega, TBI 
(18/179)8 
Longer Longer/Longer NA Higher Higher = NA 
Laxe, TBI 
(13/39)31 NA NA / Longer Longer NA NA = = 
Hinson, 
TBI(16/102)34 NA = / NA NA NA NA = NA 
Pozzi, mixed 
pediatric 
(26/407)28 
NA NA NA Higher NA NA (5) NA (5) 
Mathew, TBI 
(29/343)53 NA = / Longer NA NA NA Worse NA 
 
Table 1 legend:  
Symbols:  = :  no statistical difference; NA : not assessed; 
(1) Study details: First author, type of brain injury, (number of patients with PSH/total number of patients studied).  
(2) ‘Longer’ refers to a longer duration of mechanical ventilation or a longer length of stay, of PSH patients in 
comparison with non-PSH patients.  
(3) ‘Higher’ refers to a higher proportion of patients with tracheostomy or a higher incidence of infections, of PSH 
patients in comparison with non-PSH patients.  
(4) GOS: Glasgow outcome scale; FIM: Functional Independence Measure; ‘Worse’ refers to worse performance on 
these outcome scales, of PSH patients in comparison with non-PSH patients.  
(5) Although the pediatric case series by Pozzi et al28 did not report GOS or FIM, there was a higher incidence of 
permanent vegetative state as well as a higher mortality during follow-up.  
Pathophysiology 
Initially proposed epileptogenic mechanisms 2,13 for PSH have not found experimental support. Current 
hypotheses propose that combinations of diffuse and/or focal injury ‘disconnect’ one or more cerebral 
centres from caudal excitatory centres. 32,33,34 An initial synthesis of this hypothesis postulated a simple 
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disconnection of cortical inhibitory centres (such as the insula and cingulate cortex) with hypothalamic, 
diencephalic and brainstem centres responsible for supraspinal control of sympathetic tone.32  While this 
scheme explained aspects of PSH (such as dystonia), it failed to provide a complete explanation of all of its 
features32.  A more recent proposal, the Excitatory: Inhibitory Ratio (EIR) model33,34 proposes a two-stage 
process with the loss of descending inhibition allowing excitatory spinal circuits to develop (figure 1).  
 
 
 
Figure 2.  Excitatory-inhibitory ratio model for pathogenesis of PSH.   
In normal circumstances, various cortical, hypothalamic, thalamic, and other subcortical inputs modulate 
activity within brain stem centres (the periaqueductal grey (PAG) is shown here as one of the key brainstem 
hubs in this process). In turn, these brainstem nuclei provide inhibitory drive to spinal reflex arcs, thereby 
maintaining balance between inhibitory and excitatory interneuron influences on motor and sympathetic 
efferents, and allow normal sensory stimuli to be perceived as non-noxious. In the EIR model of PSH, 
disconnection of descending inhibition produces maladaptive dendritic arborisation and spinal circuit 
excitation, with non-noxious stimuli triggering increased motor and sympathetic output (spinally) and 
potentially becoming perceived as noxious (centrally).33,56 
 
Paroxysms then settle with recovery of the inhibitory drivers.  This model also explains the pathologically 
increased and prolonged response to stimuli that are either non-nociceptive (movement) or only minimally 
nociceptive (such as tracheal suction), as an allodynic response, reminiscent of the phenomena seen in 
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chronic pain syndromes.55 Non-PSH literature suggests a putative role for the periaqueductal grey matter 
as a central inhibitory driver,56 with midbrain lesions implicated in the functional/structural disconnection 
underlying the more severe end of the severity spectrum. It also explains some outcome differences, as 
patients with more rapid recovery of supraspinal inhibition are likely to have shorter duration PSH and 
have less brainstem involvement overall. 
 
Several attempts have been made to determine the location of structural lesions that increase the 
likelihood of developing PSH, but the data from clinical imaging are equivocal. In TBI, PSH has been variably 
associated with diffuse axonal injury (DAI) and younger age,18 and less consistently with greater focal 
parenchymal lesion burden on CT imaging,7,8  Patients with midbrain and pontine lesions are at greater 
risk of PSH,26 but incidence is also increased with lesions in the periventricular white matter, corpus 
callosum, and deep gray nuclei. Most recently, an analysis of diffusion tensor magnetic resonance imaging 
in 102 patients, 16 of whom had PSH,34 showed an association of PSH with lesions in the corpus callosum 
and posterior limb of the internal capsule. Given that the associations with PSH in these studies are all 
with markers of more severe and/or diffuse injury, it remains unlikely that any one of these lesions 
specifically drives PSH, and more likely that the development of PSH is associated with the overall burden 
of injury. These findings support the suggestion32 that PSH is a complex disconnection syndrome, with a 
contributory role for learned allodynic hyperresponsiveness (Figure 1).  
 
Several central neurotransmitter systems have been implicated in the maladaptive responses that drive 
PSH, primarily based on efficacy of specific neuromodulatory interventions (see below).  Regardless of 
these central neurotransmitter changes, there is good evidence that PSH is associated with peripheral 
catecholamine (and possibly corticosteroid) release (Figure 2a),14 which may explain the exaggerated 
responses to non-noxious or mildly noxious stimuli observed in PSH (Figure 2b).24  This suggests that 
allodynic hyperresponsiveness develops due to release of higher control, producing ‘sympathetic storms’. 
However, maladaptive spinal cord plasticity is also possible, as seen in the well-researched and related 
disorder of autonomic dysreflexia following high spinal cord injury.57 In PSH, similar spinal cord changes 
appear permanent, with sub-clinical allodynic/sympathetic over responsiveness persisting for at least 5 
years post injury.35  
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Figure 3.  
 
Pathophysiology of PSH  
(A) Median and interquartile range of normalized ratio of marker levels during paroxysms indexed to 
baseline levels. Control medians are blue diamonds and PSH patients are red boxes; all comparisons 
between these two patient groups are highly significant (p < 0.001) for all markers shown. ACTH: 
Adrenocorticotrophic hormone; NE: norepinephrine; E: epinephrine; DA: dopamine. (Replotted using data 
originally published in Reference 1414. (B) Heart rate responses in PSH. Heart rate responses (plotted as 
change from baseline) are shown following stimulation in patients recovering from traumatic brain injury 
who have normal autonomic responses (green), transient sympathetic arousal (blue; which subsides 
rapidly), and paroxysmal sympathetic hyperactivity (red) with persistent increased sympathetic response 
to non-noxious stimuli. Panel B is redrawn from data originally reported in Reference 2424. 
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Therapeutic options 
The three main goals in treatment of PSH are: to avoid the triggers that provoke the paroxysms, to mitigate 
the excessive sympathetic outflow, and to address the impact of PSH on other organ systems through 
supportive therapy. In most cases, the level of evidence for these therapeutic options is low, consisting of 
case reports or small case series, with efficacy reported in terms on anecdotal decreases in sympathetic 
hyperactivity. No randomized clinical trials (RCTs) have been conducted to date. Whether these 
interventions influence the long-term outcome in severely brain injured patients suffering from PSH is 
unclear. 
Treatments aimed at PSH may either be aimed at prevention of paroxysms, or aimed at aborting 
paroxysms that do occur.  A range of pharmacological interventions have been used for both these 
purposes, with incomplete and varying efficacy.  These are summarized in Table 3. Though individual 
agents are thought to have a greater or lesser effect on individual components of the syndrome, this 
demarcation is far from clear cut, and no agent is universally, or even predictably, effective.  In practice, 
most patients require treatment with multiple agents with potentially complementary roles – both in 
terms of different components of the syndrome, but also to combine drugs aimed at preventing and 
treating paroxysms. Individual drugs and drug combinations are typically chosen on the basis of local 
custom, rather than objective evidence. 
The majority (~80%) of PSH paroxysms occur as allodynic responses to external stimuli such as pain, urinary 
retention, or movement in both clinical8 and experimental settings.24 Where triggers can be identified (or 
suspected), it makes sense to attempt to treat or avoid them 36. Opioids, especially morphine, are probably 
the most frequently used, and often first line agents, to suppress the allodynic response in PSH patients.37  
Morphine may also have non-analgesic effects through modulation of central pathways involved in PSH 
paroxysms. Other opioids and routes of administration, such as fentanyl patches, have also been used.38 
In general, the duration of opioid therapy depends on the duration and severity of PSH symptoms, 
balanced against the desire to avoid chronic opioid use, but often extends to the rehabilitation phase. 
Other sedatives, such as midazolam, have also been used in this context.  Although haloperidol has been 
used in the past, there is concern that it may impact adversely on eventual outcome. Gabapentin, often 
used to treat neuropathic pain, has well-documented effects on presynaptic voltage-gated calcium 
channels in the dorsal horn of spinal cord, and has been used in PSH unresponsive to 
metoprolol/bromocriptine.39  
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Alpha-2-adrenergic agents act through central as well as peripheral suppression of adrenergic outflow. In 
addition, they have an imidazole receptor effect. In PSH, clonidine reduces heart rate, blood pressure and 
circulating catecholamines, but appears to be less effective in controlling temperature.  It may be less 
appropriate for paroxysmal symptoms, since it may potentiate hypotension and bradycardia between 
paroxysms, making titration challenging.36 However, clonidine patches can be effective in controlling the 
storms, even late in the course of the patient 40. Dexmedetomidine has also been reported to be effective 
in managing PSH in the ICU 41,42.  
A third class of drugs used in the treatment of PSH symptoms are non-selective beta-blocking agents. 
Propranolol is probably the most frequently used beta-blocker for this indication, and has the advantage 
of lipophilicity, which facilitates blood brain barrier penetration and central action. Schroeppel43 
demonstrated that propranolol use was independently associated with lower mortality. Beta-blockers also 
reduce the metabolic rate, which is often elevated.44,45 Cardio-selective beta-blockers such as metoprolol 
are probably less effective; combined alpha- and beta-adrenergic blockade may be better suited to 
controlling paroxysms.46 The ongoing double-blind RCT ‘Decreasing Adrenergic or Sympathetic 
Hyperactivity After Traumatic Brain Injury’ (DASH after TBI), compares combination therapy with 
propranolol and clonidine versus placebo in the ICU.47   
Other modulators of sympathetic paroxysms include the dopaminergic D2-agonist bromocriptine, which is 
variably effective in reducing temperature and sweating.32,36 Baclofen, a GABA-B agonist active at 
inhibitory interneurons in the spinal cord, has been used for refractory cases, and in three small 
prospective observational trial, continuous intrathecal Baclofen (100-200 mcg/day) was able to mitigate 
the course of PSH.48–50 Dantrolene, used in the treatment of malignant hyperthermia, may work in PSH 
through reducing intracellular calcium, with a main effect on posturing.36  A small case series from China 
reported a possible effect of hyperbaric oxygen therapy on paroxysms and posturing in early subacute 
PSH, after limited success with medical management 51. 
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Table 2.  Drugs used for treatment (Rx) and prevention (Px) of PSH 
Class Drug Prophylaxis (Px) or Treatment 
(Rx).    
Dose, route (see notes, below)  
Site of action Clinical features 
targeted 
Evidence of 
efficacy 
Cautionary notes 
Opioids Morphine (or other 
opioids; doses provided 
are for morphine)37 
Fentanyl38 
Rx: 1-10 mg bolus IV. 
Px: IV infusion, titrated to effect 
 
 
Px: Patch: 12-100 mcg/h 
Opioid receptors in brain, 
spinal cord, (+ periphery) 
Most features; 
particularly 
hypertension, 
allodynia, 
tachycardia 
Consistent Respiratory depression, 
tolerance and dose escalation 
Intravenous 
anaesthetics 
Propofol Rx: 10-20 mg bolus IV 
Px: IV infusion; max < 4 mg/kg/h 
GABA-A receptors in brain Most features Consistent Only if mechanically 
ventilated, in acute phase 
β-adrenergic 
blockers 
Propranolol43-45 
 
 
 
Labetalol46 
Px: 20-60 mg 4-6 hourly, PO 
(Rectal administration also 
described) 
 
Px: 100-200 mg 12 hourly, PO 
Non-selective β adrenoceptor 
blocker (central, cardiac, 
peripheral) 
 
β and α adrenoceptors 
Tachycardia, 
hypertension, 
diaphoresis 
May help with 
dystonia  
Consistent 
 
 
 
Limited 
Bradycardia, hypotension, 
bradyarrhythmias, sleep 
disturbances, masked 
hypoglycaemia, especially 
with oral antidiabetics 
 Metoprolol Px: 25 mg 8 hourly, PO Cardioselective  
Β adrenoceptors 
Limited or no 
impact 
Ineffective  
α -2 agonists Clonidine36 Px: 100 mcg 8-12 hourly PO; titrate 
to maximum1200 mcg/day. 
Px: IV infusion, titrate to effect 
α -2 adrenoceptors in brain 
and spinal cord 
Hypertension 
and tachycardia 
Intermediate Hypotension, bradycardia, 
sedation; IV infusions not  a 
long term solution, but 
clonidine patches may be 
useful.40 
 Dexmedetomidine41,42 Px: IV infusion titrate to effect 
0.2-0.7 mcg/kg/h 
    
Neuromodula
tors 
Bromocriptine32,36 Px: 1.25 mg PO 12 hourly;  
max 40 mg/day 
Dopamine D2 receptor 
agonist 
Inconsistent Intermediate Confusion, agitation, 
dyskinesia, nausea, 
hypotension 
 Gabapentin39 Px: 100 mg 8 hourly PO;  
max 4800mg/day 
α2δ presynaptic voltage gated 
Ca++ channels (in brain/spinal 
cord) 
Spasticity, 
allodynic 
responses 
Consistent Well tolerated 
 Baclofen48-50 Px: 5mg 8 hourly PO; max 80 mg/d 
Px: Intrathecal – specialist use only 
GABA-B agonist Spasticity, 
dystonia 
PO: Limited; 
IT: Consistent  
Sedation, withdrawal 
syndrome 
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Notes to Table 2:  
 Drug administration routes are intravenous (IV) or per orally (PO; which includes administration through a nasogastric or other feeding tube).  
Drug doses and impressions of efficacy are indicative, based on past publications (cited in the text36-51), and are largely covered in five 
reviews on the subject. 3, 36,54, 58 
 The dose ranges listed in the table cover the entire range that have been reported in the literature.  These data are provided as a record of 
what has been published, rather than as a recommendation for treatment.  Please ensure that the dosage and route of administration of 
drugs used in patients take account of individual circumstances and good clinical practice.   
 Evidence of efficacy is described as Consistent (benefit in many/most of the publications reviewed); Intermediate (where there is equivocal 
impression of benefit in the literature), Limited (when the data are limited and inconclusive, but show some benefit), or Ineffective (when 
the literature shows no benefit).   
 These judgements are necessarily subjective – a formal meta-analysis is not possible as the literature is very heterogeneous and poorly 
documented.  Not all published case reports are included, but drug classes, and specific agents, that have been commonly tried for PSH are 
covered in this table.  
 Combinations of drugs are commonly employed in clinical practice – combining interventions for both prevention and treatment of 
paroxysms, and using drugs in different therapeutic classes with different mechanisms.  These drugs and drug combinations are based on 
local custom, rather than objective evidence. 
 
 
Benzodiazepi
nes 
Diazepam,  
Lorazepam 
Midazolam 
 
Clonazepam 
Rx: 1-10 mg IV boluses 
Rx: 1-4 mg IV boluses 
Rx: 1-2 mg IV bolus 
 
Px: 0.5 – 8 mg/d PO in divided 
doses 
Central benzodiazepine 
receptor on GABA complex 
(brain and spinal cord) 
Agitation, 
hypertension, 
tachycardia, 
posturing 
Intermediate  
 
 
 
Intermediate 
Sedation; IV boluses with 
caution in subjects without 
secure artifical airway 
Sarcolemmal 
Ca++ release 
blocker 
Dantrolene36 Rx: 0.5 -2 mg/kg IV 6-12 hourly;  
maximum 10 mg/kg/day 
Blocks sarcolemmal Ca++ 
release in muscle 
Posturing and 
muscular spasm 
Intermediate Hepatotoxicity, respiratory 
depression 
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Supportive therapy to deal with the consequences of PSH is extremely important. Physiotherapy, paying 
attention to positioning of the patients to prevent contractures, and managing temperature are crucial. 
Nutritional management deserves special attention: dramatic increases in resting energy expenditure 
(REE), up to threefold baseline, have been reported during paroxysms,11 and some PSH patients admitted 
to rehabilitation units show significant weight loss of up to 25-29% following ICU management.52 Indirect 
calorimetry can guide calorie intake in proportion to increased REE. PSH increases the relative risk (RR) of 
heterotopic ossification (RR= 59.6, 95% CI=8.4–422),10 and this diagnosis should be considered in all 
patients with hot or painful joints.  
Conclusions and research agenda 
PSH is an intriguing clinical syndrome, that occurs after severe acquired brain injury of multiple etiologies, 
but most prevalent after TBI and hypoxic brain injury. Recent initiatives to define PSH with clinical criteria 
are the first steps in a longer journey to study the causes, consequences, and potential therapies for this 
condition. Potential therapeutic agents may suppress manifestations of PSH, but no prospective RCTs have 
been published regarding the potential benefits, risks, or outcome impacts of such intervention.  
The advances in clinical tools for diagnosis characterization of PSH are based on a wide clinical consensus, 
and involve most active investigators in the field.  However, linking these clinical features to lesion location 
and severity, and to clear neuropathology, remains challenging, in large part due to variable 
pathophysiology (and hence) treatment response.  Stratifying the syndrome into mechanistically 
homogeneous subgroups with common pathophysiology, diagnostic features, therapy response and 
outcome is essential if we are to pursue precision medicine approaches to its management.  However, 
accumulating the large cohorts of patients to allow such stratification is challenging.  Despite recent 
diagnostic criteria, the description of patients seems to be varied and inconsistent, especially in terms of 
imaging findings, therapies and outcome.  The use of common data elements for such description, 
borrowed from acute TBI research, and modified if needed, may represent one means of addressing this 
issue.  This approach would also allow us to define assessment tools and timings for defining early and late 
outcome, thus enabling a more rigorous epidemiological assessment of the incidence of PSH and its impact 
on outcome.  Finally, there is a need for pragmatic, but well conducted clinical trials of therapies, either 
individually, or in sequence (in an escalation pattern) to confirm or refute the putative benefit reported in 
case series or small trials.  Such studies will demand multicenter recruitment, which could make use of 
existing collaborative research networks that focus on PSH. 
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Search strategy and selection criteria 
This manuscript builds on an exhaustive review undertaken by the same group of authors in 2010.1 We conducted a 
search on MEDLINE (January 1st, 1946 to June 21st, 2017) using the following terms: 
 
(PSH OR diencephalic epilepsy OR storm OR paroxysmal sympathetic hyperactivity OR dysautonomia) 
AND (diagnosis OR definition OR treatment OR pathophysiology OR outcome) AND (brain injury OR 
stroke OR cardiac arrest OR head injury OR traumatic brain injury OR subarachnoid haemorrhage OR 
intracerebral haemorrhage) NOT (tumors OR neoplasms OR Parkinson's OR familial) 
This search yielded 975 hits, titles of which were manually searched for relevance to our review topic. The abstracts 
of the resulting 67 manuscripts were reviewed in addition to 115 manuscripts that had been identified during our 
search in 2010 (with considerable overlap between the two).  The abstracts of these manuscripts and manuscripts 
selected for review of full text by one or more of the authors, and papers selected for inclusion in this review.  No 
attempt was made to undertake a fully systematic and inclusive review. 
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Supplementary Table 1. Clinical items contributing to a diagnosis of PSH 
1. Antecedent acquired brain injury 
2. Simultaneity of clinical features 
3. Clinical features are paroxysmal in nature 
4. Sympathetic over reactivity to normally non-painful stimuli 
5. Absence of intra-paroxysmal parasympathetic features during episodes 
6. Medication is administered to decrease sympathetic features 
7. Lack of alternative explanations 
8. Features persist despite treatment of alternative differential diagnosis 
9. Features persist ≥ 3 consecutive days 
10. Features persist ≥ 2 weeks post-injury 
11. (Frequency of ≥ 2 episodes per day) 
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Supplementary Table 2: The Paroxysmal Sympathetic Hyperactivity Assessment Measure  
Component Score    0       1      2    3 Allocated 
score 
C
lin
ic
al
 
Fe
at
u
re
 
Sc
al
e
 (
C
FS
) 
Heart rate (per min) <100 100-119 120-139 >140  
Respiratory rate (per min) <18 18-23 24-29 > 30  
Systolic blood pressure (mmHg) <140 140-159 160-179 >180  
Temperature (0C) <37.0 37.0-37.9 38.0-38.9 >39.0  
Sweating Absent Mild Moderate Severe  
Posturing during episodes Absent Mild Moderate Severe  
CFS subtotal (Severity: 0 = Nil; 1-6 = Mild; 7-12 = Moderate; > 13 = Severe)  
   
D
ia
gn
o
si
s 
Li
ke
lih
o
o
d
 T
o
o
l  
(D
LT
) 
Antecedent acquired brain injury  
Clinical features occur simultaneously  
Episodes are paroxysmal in nature  
Sympathetic over-reactivity to normally non-painful stimuli  
Absence of parasympathetic features during episodes  
Features persist > 3 consecutive days  
Features persist > 2 weeks post-brain injury  
> 2 episodes daily  
Absence of other presumed causes of features  
Features persist despite treatment of alternative differential diagnoses  
Medication administered to decrease sympathetic features  
DLT Subtotal (Score 1 point for each feature present)  
  
PSH-Assessment Measure (PSH-AM = CFS subtotal + DLT subtotal)  
 
Interpretation of PSH-AM 
(CFS subtotal + DLT subtotal)  
Score PSH diagnosis 
<8 Unlikely 
8-16 Possible 
> 17 Probable 
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Supplementary Table 3: Pediatric Paroxysmal Sympathetic Hyperactivity Scoring Reference 
Score 0 1 2 3 
1-4 years 
Heart rate (per minute) <110 110-124 125-139 >140 
Respiratory rate (per minute) <30 30-34 35-39 >40 
Systolic blood pressure (mmHg) <100 100-109 110-119 >120 
Diastolic blood pressure (mmHg) <65 65-72 73-79 >80 
Temperature (°C) <37.0 37.0-37.9 38-38.9 >39.0 
Sweating Normal Increased sweating Localized diaphoresis 
Generalized 
diaphoresis 
Muscle tone increase Absent Mild increase Neat increase 
Generalized spasticity 
or opisthotons 
5-15 years 
Heart rate (per minute) <100 100-119 120-139 >140 
Respiratory rate (per minute) <25 25-29 30-34 >35 
Systolic blood pressure (mmHg) <120 120-129 130-139 >140 
Diastolic blood pressure (mmHg) <75 75-82 83-89 > 90 
Temperature (°C) <37.0 37.0-37.9 38-38.9 >39.0 
Sweating Normal Increased sweating Localized diaphoresis 
Generalized 
diaphoresis 
Muscle tone increase Absent Mild increase Neat increase 
Generalized spasticity 
or opisthotons 
This table is reconstructed based on data from Pozzi et al, Journal of Neurotrauma 2014; 31: 1897–98 
 
 
